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Chronic ulcerative colitis (CUC) is characterized by
increased intestinal epithelial cell (IEC) apoptosis as-
sociated with elevated tumor necrosis factor (TNF),
inducible nitric oxide synthase (iNOS), and p53. We
previously showed that p53 is increased in crypt IECs
in human colitis and is needed for IEC apoptosis in
chronic dextran sulfate sodium-colitis. Herein, we ex-
amined the roles of TNF and iNOS in regulating p53-
induced IEC apoptosis in CUC. The IEC TUNEL stain-
ing, caspases 3, 8, and 9, and p53 protein levels,
induced by anti-CD3 monoclonal antibody (mAb) ac-
tivation of T cells, were markedly reduced in TNF
receptor 1 and 2 gene knockout mice. Induction of
IEC apoptosis correlated with increased p53, which
was attenuated in iNOS/ mice. IEC p53 levels and
apoptosis were reduced in IL-10/ colitic mice
treated with neutralizing TNF mAb and the iNOS in-
hibitor, aminoguanidine, further suggesting that TNF
and iNOS are upstream of p53 during colitis-induced
IEC apoptosis. IEC apoptosis and p53 levels were as-
sessed in control versus untreated or anti-TNF–treated
CUC patients with equivalent levels of inflamma-
tion. Data indicated that IEC apoptosis and p53 lev-
els were clearly higher in untreated CUC but mark-
edly reduced in patients treated with anti-TNF mAb.
Therefore, TNF-induced iNOS activates a p53-depen-
dent pathway of IEC apoptosis in CUC. The inhibi-
tion of IEC apoptosis may be an important mecha-
nism for mucosal healing in anti-TNF–treated CUC
patients. (Am J Pathol 2012, 181:1306–1315; http://dx.doi.
org/10.1016/j.ajpath.2012.06.016)
1306Human inflammatory bowel diseases (IBDs) are charac-
terized by excessive crypt epithelial apoptosis, surface
ulceration, distorted crypt architecture, diarrhea, and
bleeding. Barrier disruption is linked to epithelial apopto-
sis caused by aberrant activation of innate and adaptive
immune responses.1–3 A hallmark of severe IBD is the
overproduction of tumor necrosis factor (TNF) in mucosal
tissue.2,4 The importance of TNF in disease pathogenesis
is underlined by the pronounced clinical improvement
induced when anti-TNF antibodies reduce diarrhea,
weight loss, and bleeding.4,5 At the mucosal level, anti-
TNF antibody treatment enhances mucosal healing with
rapid re-epithelialization of ulcerated surfaces. Studies
indicate some (eg, infliximab and adalimumab), but not
all (eg, certolizumab), anti-TNF agents induce apoptosis
of lamina propria cells, despite all three being able to
enhance mucosal healing.6,7 However, it remains unclear
whether the effect of anti-TNF on mucosal healing is
related to reduced epithelial apoptosis and, if so, through
what mechanism.
Overproduction of TNF in IBD has potent effects on
mucosal adaptive and innate immune responses.8,9 TNF
participates in macrophage activation by enhancing an-
timicrobial functions.10 In response to TNF, macrophages
increase production of reactive nitrosative species, such
as nitric oxide (NO) and its metabolite, peroxynitrite
(ONOO).11 Inducible NO synthase (iNOS) blockade in-
hibits disease severity and epithelial apoptosis in animal
models of IBD.12,13 Data from human IBD studies sug-
gest that NO and ONOO stabilize p53 and activate
response pathways.14,15 During tumorigenesis, NO-in-
duced mutations of p53 inactivate tumor suppressor
function, with loss of protective effects.16 Thus, TNF-me-
diated activation of iNOS may be an important pathway
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colitis-induced dysplasia.
Understanding TNF receptor signaling is complex and
difficult to apply to in vivo systems. TNF receptor 1
(TNFR1) associates with the TNF receptor–associated
death domain, which activates the extrinsic, caspase
8–linked pathway of apoptosis.17,18 However, in some
systems examined, TNF receptor–associated death do-
main is dispensable for TNF-induced apoptosis, and
cross activation of TNFRl and TNFR2 converges unto
common downstream signaling events, resulting in apop-
tosis mediated by intrinsic (mitochondrial) pathways.17,19
The proliferative zone for intestinal epithelial cells (IECs)
resides in lower crypt regions. Cellular proliferation re-
quires enhanced mitochondrial function. Given that epi-
thelial apoptosis in IBD occurs in proliferative crypt epi-
thelial cells, we suspected that pathways involving
induction of mitochondrial pathways were used. In addi-
tion, a comprehensive understanding of the role of TNF
receptor signaling within the mucosal microenvironment
requires that receptor deficiency be restricted to distinct
populations participating in mucosal immune responses.
Increased epithelial crypt cell apoptosis commonly oc-
curs in ulcerative colitis (UC) and Crohn’s disease.20,21
Numerous in vitro and in vivomodel systems have studied
this phenomenon, suggesting that TNF-mediated path-
ways play key roles in inducing programmed cell death in
epithelial crypts. To model these pathways, a well-char-
acterized model of T-cell activation was used that in-
duces transient stem/progenitor cell activation, crypt IEC
proliferation, and TNF-mediated diarrhea reminiscent of
human IBD.22,23 The reproducible kinetics of the model
permitted identification of the events in immune-mediated
apoptosis and allowed application to relevant gene
knockout models. We recently reported that p53 is the
major mediator of colonic crypt IEC apoptosis in colitis.24
This article examines the upstream events leading up to
p53 activation and IEC apoptosis. Results suggest a
mechanism by which TNF signals, through both TNFR1
and TNFR2, stimulate iNOS-mediated p53-dependent
apoptosis of crypt IECs. Studies in the IL-10/ murine
model of colitis confirmed that TNF-induced iNOS led to
activation of p53 and induced IEC apoptosis. Finally, we
confirm that TNF-induced p53-mediated apoptosis also
occurs in vivo during human UC. Overall, the findings
suggest that T-cell activation causes TNF and iNOS-me-
diated stabilization of p53, followed by p53-mediated
crypt cell apoptosis in IBD. These data have direct rele-
vance to mechanisms of barrier disruption, ulceration,
and initiation of dysplasia seen in p53 mutant crypts.
Materials and Methods
Mice and Treatments
C57BL/6, TNFR1-knockout (TNFR1/), TNFR2-knockout
(TNFR2/), combined TNFR1/2-knockout (TNFR1/2/),
iNOS-knockout (iNOS/), p53-knockout (p53/), and
IL-10–knockout (IL-10/) mice on the C57BL/6 back-
ground (10 generations) were obtained from the Jack-son Laboratory (Bar Harbor, ME) and screened for the
absence of wild-type (WT) gene before use. Mice were
maintained in barrier housing in the Northwestern Univer-
sity Center for Comparative Medicine (Chicago, IL), in
accordance with guidelines of the Northwestern Univer-
sity Animal Care and Usage Committee. To model acute
inflammation, mice were given i.p. injections of 0.2 mg
hamster anti-CD3 monoclonal antibody (mAb; 145-2C11)
or control hamster mAb (UC8-IB9) and sacrificed at dif-
ferent time points, as previously described.23 Anti-CD3
and control antibodies were purified from cell culture
supernatant over a protein G column (GBioscience, St.
Louis, MO). In some mice, the iNOS inhibitor, L-N6-(1-
iminoethyl) lysine (L-NIL), was given i.p., 0.2 mg 2 hours
before and at the time of anti-CD3 mAb treatment. IL-
10/ mice were moved to conventional housing 1 week
before starting piroxicam chow feeding. To accelerate
and synchronize the onset of colitis, IL-10/ mice were
fed 60 mg of piroxicam (Sigma, St Louis, MO)/250 g of
rodent powdered chow for 1 week and then 80 mg of
piroxicam/250 g of chow for another week. Controls were
given powdered chow for only 2 weeks. Mice then re-
sumed standard pelleted chow and were examined on
days 28 and 46 after day 1 of piroxicam feeding. For
chronic dextran sulfate sodium (DSS)-colitis, one cycle
constituted giving the mice 2.0% DSS in their drinking
water for 7 days, followed by 14 days of regular water.
This was done three times, and the mice were sacrificed
at the end of the third cycle. Aminoguanidine was admin-
istered at 200 g/day for 2 days, and the mice were
sacrificed 12 hours after the last injection. Anti-TNF, 0.2
mg, was injected into WT mice 24 hours before anti-CD3
treatment, and 0.5 mg of anti-TNF was administered at 36
hours or 1 week, as indicated, before the mice with colitis
were sacrificed.
Immunohistochemical Localization of Apoptotic
Cells
Formalin-fixed, paraffin-embedded sections were stained
for apoptotic cells using the TUNEL method for visualiz-
ing the 3=-OH ends of DNA fragments. After digestion in
proteinase K, sections were rinsed and incubated with
0.3% H2O2 at room temperature for 20 minutes. Sections
were incubated in a terminal deoxynucleotide mixture
(Roche Diagnostics Corp., Indianapolis, IN), followed by
anti-fluorescein mAb conjugated with horseradish perox-
idase, then 3=,3=-diaminobenzidine as immunodetection
substrate.25 Apoptotic indexes were calculated as the
number of TUNEL-positive epithelial cells/total number of
epithelial cells, multiplied by 100, to yield the apoptotic
index. A total of five mice (four for IL-10/ experiments)
were analyzed in each group, and a minimum of 8 to 20
well-oriented crypts were counted for each mouse. The
data are presented as the mean  SEM.
Real-Time PCR and Primers
Total RNA from sonicated tissue was isolated using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). The high-
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CA) was used to synthesize cDNA. Expression of genes
was determined by real-time quantitative PCR using the
ABI 7500 Real Time PCR system and the Power SYBR
Green PCR master mix (Applied Biosystems). Primers
were selected based on nucleotide sequences down-
loaded from the National Center for Biotechnology In-
formation data bank for TNF- (forward primer, 5=-
CCCAGGGACCTCTCTCTAATCA-3=; reverse primer,
5=-GGTTTGCTACAACATGGGCTACA-3=) and iNOS
(forward primer, 5=-CAAGTACGGCCGCTTCGA-3=; re-
verse primer, 5=-CACTCGTATTTGGGATGTTCCA-3=).
For each sample assayed, the threshold value (CT) for
target genes and glyceraldehyde-3-phosphate dehy-
drogenase (internal reference) was determined. All as-
says were performed in triplicate.
WB Analysis and Antibodies
Small-bowel (SB) epithelial cells were isolated by the
EDTA method, depleted on sheep anti-rat IgG magnetic
Dynabeads (Life Technologies, Grand Island, NY) pre-
loaded with rat anti-mouse CD45 antibodies, and homoge-
nized in radioimmunoprecipitation assay buffer containing
protease and phosphatase inhibitor cocktail (GBiosci-
ence).15 Homogenates were centrifuged at 15,700  g for
30 minutes. Proteins were separated by SDS-PAGE using
8% to 16% precast gels (Lonza, Basel, Switzerland) and
transferred to polyvinylidene difluoride membrane (EMD
Millipore, Billerica, MA). The membranes were blocked with
protein-free T20 blocking buffer (Thermo Scientific, Rock-
ford, IL) and incubated with primary antibodies specific for
iNOS (BD Transduction Laboratories, San Jose, CA), p53
and nitrotyrosine (Cell Signaling), p-p53 (Ser 15; Santa Cruz
Biotechnology Inc., Santa Cruz, CA), caspase 3 (cleaved
fragment 17, 19 kDa; proform, 35 kDa; Cell Signaling, Dan-
vers, MA), caspase 9 (37 kDa; Cell Signaling), and caspase
8 (20 kDa; Abcam, Cambridge, MA), followed by a corre-
sponding anti-rabbit or anti-mouse IgG (Pierce Protein Re-
search Products, Rockford, IL). The membranes were
stripped and probed with -actin (Sigma-Aldrich, St. Louis,
MO) as a loading control. Proteins were detected by chemi-
luminescence (West Pico or West Dura kits; Pierce) on
autoradiography film digitally scanned for quantification by
densitometry using Adobe Photoshop (Adobe Systems Inc,
San Jose, CA) analysis tools. Each Western blot (WB) was
repeated at least three times.
Human Colonic Specimens and Histological
Score
Biopsy specimens were obtained from human patients
aged 18 years, undergoing diagnostic or surveillance
colonoscopy for UC or therapeutic colonic resection, or
healthy individuals undergoing routine colon cancer sur-
veillance. Exclusion criteria were pregnant women, history
of intestinal surgery, bleeding diathesis, or coagulopathy.
Inflammation was scored by a blinded researcher (P.S.) on
a scale from 0 to 8, based on mucosal leukocyte infiltration
(0, no infiltration; 1, basolateral; 2, infiltration halfway up thecrypt; 3, diffuse infiltration; and 4, crypt abscess) added to
a crypt architecture score (0, no epithelial cell distortion; 1,
crypt hyperplasia; 2, mild crypt distortion; 3, severe crypt
distortion; and 4, complete loss of crypt structure). All un-
treated and anti-TNF–treated patients were inflamed and
had a mean histological score greater than four. A total of
six specimens from six patients were analyzed for each
group. Collection of all patient materials for this study was
approved by Northwestern University’s Office for the Pro-
tection of Human Subjects.
Statistical Analysis
A two-tailed Student’s t-test was used to evaluate differ-
ences between the groups. For any single experiment, up
to five statistical comparisons were made. Bonferroni cor-
rection for multiple comparisons results in differences
being considered statistically significant when P  0.01.
This would control the overall type I error rate for an
experiment at 5%.
Results
TNF-Mediated Crypt Cell Apoptosis Is TNFR1
and TNFR2 Dependent
To examine the relative contribution of TNFR1 and TNFR2
signaling to T-cell–induced IEC apoptosis, WT, TNFR1/,
TNFR2/, or TNFR1/2/ mice, we stimulated with anti-
CD3 mAb to activate T cells. Researchers reported that
treating mice with anti-CD3 increases intestinal (epithelial
and lamina propria) and serum levels of cytokines, includ-
ing TNF.26–29 At 24 hours after injection, TUNEL staining of
the SB of WT mice indicated that T-cell activation induced
IEC apoptosis in lower to mid crypt regions (Figure 1A). By
comparison, epithelial cell apoptosis was reduced in mice
deficient for TNFR1 or TNFR2 (Figure 1A). Although individ-
ual TNFR1 or TNFR2 deletions reduced apoptotic re-
sponses by approximately 45%, mice with combined
TNFR1 and TNFR2 deficiencies exhibited 60% less apop-
tosis (Figure 1B). Thus, both TNFR1 and TNFR2 contributed
to T-cell–mediated IEC apoptosis in the SB.
Next, caspase 3, 8, and 9 activation was assessed in
IECs as an indicator of intrinsic and extrinsic apoptotic
signaling pathways. The WB analysis of IEC isolates from
control and anti-CD3-treated mice revealed that T-cell
activation induced IEC caspase 3 cleavage 30-fold in WT
mice (Figure 1C). Densitometry showed that caspase 3
cleavage persisted from 3 to 12 hours after treatment,
consistent with times when proteins became nitrated (see
Supplemental Figure S1A at http://ajp.amjpathol.org)26,30
and with times we reported that anti-CD3 induced TNF
locally.26 By comparison, TNFR deficiency largely atten-
uated caspase 3 cleavage at every time point. The results
of caspase 9 cleavage paralleled those of caspase 3
reductions seen in TNFR-deficient mice (Figure 1C; see
also Supplemental Figure S1B at http://ajp.amjpathol.org).
In contrast, IEC caspase 8 cleavage (p20 protein shown
herein) was unaffected by T-cell activation. Together,
these data indicated that both TNFR1 and TNFR2 signal-
, 8, and
Epithelial Cell Apoptosis in IBD 1309
AJP October 2012, Vol. 181, No. 10ing mediated IEC apoptosis via caspases 3 and 9. Not all
apoptotic activity was abrogated by TNFR deficiency.
These data suggested that, although TNFR signaling was
important for IEC apoptosis, other pathways contributed
as well (eg, Fas/FasL and perforin).31
TNF-Induced iNOS Mediated Immune-Mediated
Crypt Cell Apoptosis
Next, we tested the hypothesis that TNF-induced iNOS
contributed to T-cell–induced epithelial apoptosis. TNF
and iNOS mRNA levels in anti-CD3-stimulated TNFR1/2/
and iNOS/ mice were assessed. The expression of
iNOS was significantly reduced in TNFR1/2/ mice rel-
ative to WT, whereas TNF levels were induced in WT,
TNFR1/2/, and iNOS/mice (Figure 2A). WB analysis
revealed that iNOS protein levels increased within 3
hours of T-cell activation in WT mice (Figure 2B). By
comparison, iNOS induction was significantly reduced in
the single and double TNF receptor knockout mice (Fig-
ure 2B). Therefore, TNFR1 and TNFR2 signaling induced
iNOS after T-cell activation.
Next, we determined whether iNOS mediated T-cell–
induced IEC apoptosis. Data shown in Figure 3A indicate
that IEC apoptosis levels were significantly reduced
when iNOS was blocked either pharmacologically with
the selective inhibitor L-NIL or genetically using iNOS
deficient relative to WT control mice. Furthermore, acti-
vation of caspases 3 and 9 was attenuated in iNOS/
A
TNFR1-/- + anti-CD3 TNFR2-/- + anti-CD3
TNFR1/2-/- + anti-CD3
WT + anti-CD3WT
TNFR1/2-/-
C
B
17
20
37
Figure 1. TNFR1 and TNFR2 signaling induces TNF-mediated crypt cell ap
or anti-CD3 antibody and sacrificed at the indicated time points. A: TUNEL
The apoptotic index is determined based on counting TUNEL-positive cells.
WT mice compared with untreated WT mice. C: WB of activated caspases 3
-Actin is used as a loading control.mice compared with anti-CD3-treated WT mice (Figure3B). Procaspase 3 protein levels were induced by im-
mune activation in WT mice and in iNOS/ mice, albeit
to lesser degrees over time. Therefore, procaspase 3
expression may be regulated by inflammatory mediators
in IECs. Caspase 8 activation (p20 activated form) re-
mained unchanged at every time point in IECs from both
WT and iNOS/ mice. Taken together, these data sug-
gested that TNF-induced iNOS mediated IEC apoptosis
after T-cell activation.
TNFR1, TNFR2, and iNOS-Induced IEC
Apoptosis Is p53 Dependent
Data in other tissues, such as the brain, pancreas, and
heart, suggested that iNOS-induced nitrosative oxygen
species induced p53 protein stabilization, which then
induced apoptosis.32 We recently reported that p53 was
an important mediator of inflammation-induced apoptosis
in the colon; however, the upstream mechanisms re-
mained unknown.24 Data herein suggested that both
TNFR1 and TNFR2 contributed to IEC apoptosis via the
intrinsic pathway; thus, we examined p53 protein levels in
IECs after anti-CD3 treatment. Data in Figure 4 showed
that T-cell activation induced a progressive increase in
p53 from 3 to 12 hours in the SB of WT mice. By com-
parison, p53 stabilization was severely attenuated in TNF
receptor or iNOS-deficient mice (Figure 4A). These re-
sults were consistent with TNF and iNOS being upstream
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for p53 in IEC apoptosis was explored by TUNEL stain-
ing. Although IEC apoptosis increased in lower to mid
crypts of tissue after T-cell activation, TUNEL staining of
IECs was reduced approximately 89% in p53/ mice
(Figure 4, B and C). WB analysis confirmed p53-depen-
dent IEC apoptosis because caspase 3 and 9 activation
was significantly attenuated in p53/ mice compared
with WT (Figure 4D). Taken together, these data were
consistent with the notion that p53 mediated IEC death in
response to TNF and iNOS signaling.
TNF and iNOS Are Required for
Colitis-Induced IEC Apoptosis
To determine the relevance of these findings to IBD coli-
tis, IEC apoptosis was assessed in IL-10/ mice. Colitis
was induced by feeding mice piroxicam for 14 days.33,34
TUNEL staining revealed that, on the day of peak colitis
(day 28), apoptosis increased within IECs localized to
lower crypt regions (Figure 5A). To determine whether
iNOS or TNF signaling contributed to colitis-induced
apoptosis, mice were treated with either aminoguanidine
(a specific iNOS inhibitor) or anti-TNF antibody, respec-
tively. TUNEL staining revealed that apoptotic indexes
decreased by 58% in aminoguanidine-treated mice and
37% in anti-TNF–treated mice, compared with untreated
colitic mice (Figure 5, A and B). Short-term blocking of
TNF by anti-TNF treatment was also effective at reducing
apoptosis in the anti-CD3 model, as determined by
TNFR1/2-/- iNOS-/-
ND
WT
A
B
β-actin
WT     
iNOS
0     3    0    3    0   3    0    3Anti-CD3, hrs:
130  
Figure 2. iNOS mediates T-cell–induced crypt cell apoptosis downstream of
TNFR1 and TNFR2. A: Fold induction of iNOS and TNF mRNA expression 3
hours after anti-CD3 injection determined by real-time RT-PCR from SB tissue
from WT, TNFR1/2/, and iNOS/ mice. B: WB analysis of iNOS protein
expression in the indicated mice before, or 3 hours after, T-cell activation.
-Actin is used as a loading control. ND, not determined.TUNEL staining (see Supplemental Figure S2A at http://ajp.amjpathol.org). Analysis of cleaved caspases 3 and 9
in colitic mice confirmed that anti-TNF or aminoguanidine
treatment decreased IEC apoptosis in colitic mice (Figure
5C). The expression of caspase 8 active polypeptide
(p20) remained unchanged. Quantitative analysis of TNF-
induced iNOS mRNA expression revealed that anti-TNF
treatment of mice reduced downstream effects of TNF
and, thus, colitis-induced epithelial iNOS gene transcrip-
tion (see Supplemental Figure S2B at http://ajp.amjpathol.
org). These data were also confirmed in another chronic
colitis model. Mice that underwent three cycles of DSS in
their drinking water revealed that anti-TNF reduced ex-
pression of relevant gene targets (TNF,mmp7, and iNOS;
see Supplemental Figure S2C at http://ajp.amjpathol.org).
Furthermore, anti-TNF abrogated elevated levels of epi-
thelial cleaved caspases 3 and 9 in mice with chronic
DSS-colitis (Figure 5D). Together, these data suggested
that TNF and iNOS mediated IEC apoptosis in colitis.
To determine whether iNOS and TNF regulated IEC
p53 levels in colitis, IEC lysates were analyzed by WB.
Cytoplasmic p53 levels were much higher with colitis
(Figure 5C). Significantly, anti-TNF and aminoguanidine
treatment reduced p53 accumulation in the cytoplasm.
These data were further supported by findings in three-
cycle DSS-treated mice in which anti-TNF treatment
abrogated colitis-induced IEC p53 stabilization (Figure
5D). In summary, these data illustrated that TNF-in-
duced p53-mediated signaling accounted for IEC
apoptosis in colitis.
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caspases 3, 8, and 9 is assessed by WB for the cleaved forms of the indicated
/protein in WT and iNOS mice at 0, 3, 6, or 12 hours after T-cell activation.
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Dependent in Human UC
To examine a role for TNF to induce p53-mediated IEC
apoptosis in human UC, IEC apoptosis and p53 staining
were compared between control tissue and actively in-
flamed colitis tissue from untreated patients or those re-
ceiving anti-TNF therapy. All UC samples chosen for this
study had moderately active inflammation, as determined
by histological scores (Figure 6; see also Materials and
Methods). Thus, levels of tissue inflammation were similar
between untreated and anti-TNF–treated tissue. Patients
undergoing routine surveillance colonoscopy rarely dis-
played TUNEL- or p53-positive cells (Figure 6). Apoptotic
cells were seen primarily in plateau regions, whereas p53
was detected in lower crypts. Strikingly, colitis increased
IEC apoptosis and p53 staining throughout lower and mid
crypt regions (Figure 6). By comparison, IEC apoptosis
and p53 staining were markedly reduced in patients
treated with anti-TNF pharmacological agents. These
data indicated that, despite equivalent levels of inflam-
mation, anti-TNF Ab treatment reduced p53-mediated
IEC apoptosis in human UC (Figure 6D).
Discussion
The intestinal epithelium provides essential roles impor-
tant for host defense and homeostasis, including main-
taining barrier function and participating in mucosal im-
WT                T
0    3     6    12     0
A
anti-CD
W
T
p5
3-
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Untreated
Anti-CD3, hrs:
B
53 
42 
Figure 4. p53 Plays a role in T-cell–induced crypt cell apoptosis downstr
stabilization in SB IECs from WT, TNFR1/2/, and iNOS/ mice. B: Apopto
after stimulation with anti-CD3 mAb injection relative to WT mice. Insets:
picture. C: Results are quantified by counting TUNEL-positive cells to deter
analysis at the indicated times after anti-CD3 injection. -Actin is used as amune responses.1,2 Regulation of apoptosis of IECs isone way that the intestinal epithelium maintains or re-
turns to homeostasis.35 During IBD, apoptosis is ob-
served in acute inflammatory sites.35,36 Therapy with
TNF-neutralizing antibody effectively reduces IEC
apoptosis and increases mucosal repair; however, the
mechanisms for TNF-mediated tissue injury in IBD re-
main unclear.37,38 Recent findings from our laboratory
indicate that p53 is the predominant mediator of IEC
apoptosis in IBD.24 The data presented herein suggest
that TNF-induced iNOS stabilizes p53, which induces
crypt IEC apoptosis (Figure 6D).
We show that p53 is a major mediator of inflammation-
induced crypt IEC apoptosis. Previous reports showed
elevated levels of p53 in patients with UC.15,16,24,39 Most
significantly, we report a role for p53 in both an acute and
chronic inflammatory model in mice that parallels these
observations made from studying human disease and is,
thus, clinically relevant. First, p53 levels were elevated in
anti-CD3-treated and IL-10/mouse colitis models (Fig-
ures 1 and 5). Second, p53 deficiency reduced IEC
apoptosis, as measured by TUNEL staining and WB of
activated caspase 3 and 9 cleavage (Figure 4). Finally,
regions of elevated p53 staining in patients with UC cor-
related with increased IEC apoptosis, and regions of
reduced p53 paralleled reductions in IEC apoptosis after
anti-TNF therapy (Figure 6). Taken together, these data
further implicate p53 as a key player in IBD crypt IEC
apoptosis.
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colon in epithelial cells, lamina propria mononuclear
cells, and neutrophils.14,15 Reductions of iNOS mRNA
and protein in mice with T-cell–stimulated TNFR1/2/
and anti-TNF–treated colitis suggest that TNF is a major
mediator of iNOS in intestinal inflammation. Data pre-
sented herein in two mouse models directly implicate
iNOS in inflammation-induced IEC apoptosis. IEC apop-
tosis was reduced in iNOS-deficient mice (Figure 3) and
in mice treated with the specific inhibitors, L-NIL or ami-
noguanidine (Figure 5). Furthermore, p53 protein stabiliza-
tion was attenuated in iNOS/ mice treated with anti-CD3
and in colitic IL-10/ mice treated with aminoguanidine.
These data confirm that NO and ONOO actively partici-
pate in p53 stabilization. In fact, Singer et al14 previously
demonstrated markedly elevated nitrotyrosine staining (a
product of ONOO) in IECs from patients with IBD. Thus,
the effects of ONOO likely directly affected p53 stabiliza-
tion within IECs. Inhibition of p53 stabilization and caspase
activation by L-NIL and aminoguanidine was incomplete.
These data suggest that iNOS-independent mechanisms
may also have some role in inflammation-induced apoptosis
of IECs.
Our data indicate that inflammation-induced TNF is an
important inducer of p53-dependent IEC apoptosis. Pre-
viously, expression of both TNFR1 and TNFR2 was in-
creased on IECs during inflammatory conditions.41,42 Our
analysis reveals that signaling through both receptors
contributes to inflammation-induced IEC apoptosis be-
cause apoptosis was decreased in the single- and dou-
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left untreated or treated with anti-TNF mAb, and levels of p53 and cleavedble-receptor knockouts after T-cell activation and by anti-TNF treatment in the IL-10/ chronic colitis model.
These data are consistent with reports showing that
TNFR1 and TNFR2 cooperate in TNF-mediated apoptosis
and also form functional heterocomplexes.19,43–45 Most
significantly, TNF neutralization in patients with UC re-
duced IEC apoptosis and p53 staining (Figure 6, A–C).
These data indicate a direct role for TNF in IEC apoptosis
through p53-mediated pathways (Figure 6D).
In our experiments, data suggest that the mitochon-
drial intrinsic pathway mediated inflammation-induced
IEC apoptosis. We consistently saw, in murine models,
that inflammation induced procaspase 3 and 9, but not 8,
cleavage into their active forms. Caspase 8 primarily
induces apoptotic death initiated by receptors containing
death domains (eg, TNFR1, Fas, and DR5).46 Its activa-
tion, for example, mediates caspase 3 and BH3 interact-
ing-domain death agonist cleavage, leading to the exe-
cution of apoptosis. Therefore, the absence of caspase 8
cleavage suggests that although TNFR1 was required, it
did not induce caspases linked to the extrinsic pathway.
Rather, our data indicate that TNFR-mediated IEC apop-
tosis required activation of the intrinsic or mitochondrial
pathway. Mitochondrial dysfunction initiates apoptosis by
the intrinsic apoptotic pathway and includes p53 trans-
location to the nucleus, where the protein modulates pro-
and anti-apoptotic Bcl-2 family proteins.47 This pathway
is tightly regulated by a balance between prosurvival and
pro-apoptotic Bcl-2 family members.48 Some evidence
suggests that p53 requires apoptotic protease activating
factor 1, caspase-9, and cytochrome c release to perform
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AJP October 2012, Vol. 181, No. 10dependent apoptosis and tumor suppression. It was pre-
viously reported that TNF-induced IEC apoptosis was
only TNFR1 dependent and p53 independent, results that
contradict those reported herein.50 It is possible that the
epithelial populations undergoing apoptosis in these
studies differed from those examined herein. Piguet et
al50 induced villus IEC apoptosis and detachment by a
relatively high-dose TNF injection; however, in our exper-
iments, we observed the increase in apoptosis in IECs in
the lower crypt regions, as seen in patients with human
IBD. Because villus IEC apoptosis occurs after ischemia
reperfusion, their studies likely present a valid model for
this mode of IEC death. Conversely, the models used
herein result in crypt IEC death and, therefore, more
closely resemble mechanisms of IEC apoptosis in IBD.
One clinical implication of these studies is that com-
monly used therapeutic agents that block TNF (anti-TNF
monoclonal antibody) or iNOS (mesalamine) may en-
hance mucosal healing by reducing IEC apoptosis.7,51
Our studies show that TNF induces iNOS, which activates
p53 in epithelial cells (Figure 6D). These mediators, in-
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chronic inflammation from UC induces TNF production, which causes incre
p53 protein in crypt epithelial cells. Points in the pathway where the therapcreased in IBD, induce IEC apoptosis by activating p53in lower and mid crypt zones, where proliferation is in-
duced. Thus, we strongly believe that IEC apoptosis in
the lower and mid crypts is most relevant to the increased
epithelial cell death seen in human IBD. It is, therefore,
attractive to speculate that p53-mediated signaling in-
duces apoptosis in proliferating progenitor populations.
In biopsy specimens from patients with UC, we failed to
see a correlation between p53 status (in a sample from
anti-TNF–treated patients) and histological activity. In
other reports,52,53 investigators found that mucosal in-
flammation was unaffected by p53 status; thus, the pre-
dominant effect of p53 function and IEC apoptosis may
be on the development of dysplasia. In this scenario, a
failure to induce apoptosis might allow for a long-lived
progenitor cell population harboring DNA mutations to
persist.
Chronic colitis induced in mice by DSS alone initiates
the neoplastic process,54 as does colitis in IL-10/
mice, suggesting that inflammation plays a key role in
colitis-associated cancer development.54,55 Mutation
of the tumor suppressor gene, p53, is an early event in
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AJP October 2012, Vol. 181, No. 10cer.16,56–59 We show herein that stabilization of epithelial
p53 after immune activation is TNFR1/2 and iNOS depen-
dent. Without p53 function, as would be the case after
inflammation-induced p53 mutation, damaged proliferat-
ing cells would avoid apoptosis. Chen et al60 showed
clonal expansion of p53-mutated epithelial cells in areas
of colitis-induced dysplasia. The failure of p53-mutated
IECs to undergo apoptosis may explain why IEC apop-
tosis is reduced in colonic tumor samples and carcino-
mas.35 In fact, loss of p53 enhanced cancer rates in mice
with DSS colitis.52,61 Additional exploration of p53-defi-
cient mice in chronic colitis models will further discern the
role p53 plays in IBD-induced oncogenesis.
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